Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Andrew G. Sikora is active.

Publication


Featured researches published by Andrew G. Sikora.


JAMA Oncology | 2015

Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus–Related Oropharyngeal Carcinoma

Eleni M. Rettig; Alicia Wentz; Marshall R. Posner; Neil D. Gross; Robert I. Haddad; Maura L. Gillison; Carole Fakhry; Harry Quon; Andrew G. Sikora; William Stott; Jochen H. Lorch; Christine G. Gourin; Yingshi Guo; Weihong Xiao; Brett A. Miles; Jeremy D. Richmon; Peter E. Andersen; Krzysztof Misiukiewicz; Christine H. Chung; Jennifer Gerber; Shirani D. Rajan; Gypsyamber D'Souza

IMPORTANCE Human papillomavirus-related oropharyngeal carcinoma (HPV-OPC) is increasing in incidence in the United States. Although HPV-OPC has favorable prognosis, 10% to 25% of HPV-OPCs recur. Detection of human papillomavirus (HPV) DNA in oral rinses is associated with HPV-OPC, but its potential as a prognostic biomarker is unclear. OBJECTIVE To determine whether HPV DNA detection in oral rinses after treatment for HPV-OPC is associated with recurrence and survival. DESIGN, SETTING, AND PARTICIPANTS Prospective cohort study of patients with incident HPV-OPC diagnosed from 2009 to 2013 at 4 academic tertiary referral cancer centers in the United States. Oral rinse samples were collected at diagnosis and after treatment (9, 12, 18, and 24 months after diagnosis), and evaluated for HPV DNA. Among an initial cohort of 157 participants with incident HPV-OPC treated with curative intent, 124 had 1 or more posttreatment oral rinses available and were included in this study. MAIN OUTCOMES AND MEASURES Disease-free survival (DFS) and overall survival (OS) were estimated by the Kaplan-Meier method, and the association of HPV DNA detection in oral rinses with survival was evaluated using Cox regression analysis. RESULTS Oral HPV type 16 (HPV16) DNA was common at diagnosis (67 of 124 participants [54%]). In contrast, oral HPV16 DNA was detected in only 6 participants after treatment (5%), including 5 with HPV16 DNA also detected at diagnosis (persistent oral HPV16 DNA). Two-year DFS and OS were 92% (95% CI, 94%-100%) and 98% (95% CI, 93%-99%). Persistent oral HPV16 DNA was associated with worse DFS (hazard ratio, 29.7 [95% CI, 9.0-98.2]) and OS (hazard ratio, 23.5 [95% CI, 4.7-116.9]). All 5 participants with persistent oral HPV16 DNA developed recurrent disease, 3 with local disease involvement. In contrast, just 9 of 119 participants (8%) without persistent oral HPV16 DNA developed recurrent disease, only 1 (11%) with local disease involvement. Median (range) time from earliest posttreatment oral HPV16 DNA detection to recurrence was 7.0 (3.7-10.9) months. CONCLUSIONS AND RELEVANCE Human papillomavirus type 16 DNA in oral rinses is common at diagnosis but rare after treatment for HPV-OPC. Our data suggest that, although infrequent, persistent HPV16 DNA in posttreatment oral rinses is associated with poor prognosis and is a potential tool for long-term tumor surveillance, perhaps more so for local recurrence.


Mucosal Immunology | 2015

Phenotype and function of nasal dendritic cells

Haekyung Lee; Darren Ruane; Kenneth Law; Yan Ho; Aakash Garg; Adeeb Rahman; Daria Esterházy; Cheolho Cheong; Erden Goljo; Andrew G. Sikora; Daniel Mucida; Benjamin Chen; Satish Govindraj; Gaëlle Breton; Saurabh Mehandru

Intranasal (i.n.) vaccination generates immunity across local, regional, and distant sites. However, nasal dendritic cells (DCs), pivotal for the induction of i.n. vaccine-induced immune responses, have not been studied in detail. Here, by using a variety of parameters, we define nasal DCs in mice and humans. Distinct subsets of “classical” DCs, dependent on the transcription factor zbtb46 were identified in the murine nose. The murine nasal DCs were Fms-related tyrosine 3 kinase ligand responsive and displayed unique phenotypic and functional characteristics, including the ability to present antigen, induce an allogeneic T-cell response, and migrate in response to lipopolysaccharide or live bacterial pathogens. Importantly, in a cohort of human volunteers, BDCA-1+ DCs were observed to be the dominant nasal DC population at steady state. During chronic inflammation, the frequency of both BDCA-1+ and BDCA-3hi DCs was reduced in the nasal tissue, associating the loss of these immune sentinels with chronic nasal inflammation. The present study is the first detailed description of the phenotypic, ontogenetic, and functional properties of nasal DCs, and will inform the design of preventative immunization strategies as well as therapeutic modalities against chronic rhinosinusitis.


Annals of Internal Medicine | 2017

Oral Human Papillomavirus Infection: Differences in Prevalence Between Sexes and Concordance With Genital Human Papillomavirus Infection, NHANES 2011 to 2014

Kalyani Sonawane; Ryan Suk; Elizabeth Y. Chiao; Jagpreet Chhatwal; Peihua Qiu; Timothy Wilkin; Alan G. Nyitray; Andrew G. Sikora; Ashish A. Deshmukh

Human papillomavirus (HPV) infection causes cancer at several anatomical sites, including the oropharynx, anus, and penis in men and the oropharynx, anus, cervix, vagina, and vulva in women (1). Between 2008 and 2012, an average of 38793 cases of HPV-related cancer were diagnosed annually in the United States, 23000 (59%) in women and 15793 (41%) in men (2). Among these cases, the most common cancer was oropharyngeal squamous cell carcinoma (OPSCC), of which there were 3100 cases in women and 12638 in men (2). The incidence of HPV-related OPSCC among women generally plateaued (with a statistically insignificant increase of 0.57% per year) from 2002 to 2012 (3). In contrast, the incidence among men (7.8 per 100000) has increased dramatically (2.89% per year) and has already surpassed the incidence of cervical cancer in women (7.4 per 100000) (3). The increase in annual incidence was particularly high in men aged 50 to 59 years: 7.75% from 2002 to 2004 and 2.44% from 2004 to 2010 (3). These incidence trends are projected to continue and not reverse until after 2060, making OPSCC a significant public health concern (4, 5). Recent evidence shows that prophylactic HPV vaccination seems to protect against infection with vaccine-covered oral HPV subtypes (6) and thus holds promise for reversing the rising OPSCC incidence among men in the long term; however, the low uptake rate of the vaccine among boys remains a concern (79). Furthermore, the great majority of persons at risk for OPSCC are older than 26 years (4) and do not qualify for HPV vaccination or may already have been exposed to HPV. For this reason, epidemiologic studies on oral HPV infection are needed to guide the design and development of alternative OPSCC prevention strategies targeted toward persons at high risk. Examining the relationship between HPV infections occurring at different anatomical sites also is crucial to understanding HPV transmission dynamics. Therefore, our objective was twofold: to estimate the population-based prevalence and risk factors of oral HPV infection by sex and sexual orientation and to characterize the concordance of oral and genital HPV infection from the NHANES (National Health and Nutrition Examination Survey). Methods Survey Design and Population The NHANES is conducted by the National Center for Health Statistics of the Centers for Disease Control and Prevention to monitor the health and nutritional status of the U.S. population. Participants in NHANES 2011 to 2014 were noninstitutionalized U.S. civilians identified through a stratified, multistage probability sampling technique. Participants aged 18 to 69 years had a physical examination at a mobile examination center (MEC), followed by a household interview. Hispanic persons, African Americans, persons with low income, and those aged 60 years and older were oversampled to allow sufficient sizes for subgroup analysis. The medical examinations done at the MEC included medical, dental, and physiologic measurements and laboratory tests administered by highly trained medical personnel. The household interview component consisted of standardized questionnaires on demographics, socioeconomic status, diet, and sexual behavior administered through a personal or phone interview. Demographic and Behavioral Data The NHANES collected demographic data through a standard questionnaire administered in-home by trained interviewers using a computer-assisted personal interviewing system. Data on cigarette, alcohol, and marijuana use were collected during the MEC self-interview. Demographic data included age at the time of the interview, sex, race, marital status, and income. Income-to-poverty ratio was calculated by dividing income by the poverty guidelines of the U.S. Department of Health and Human Services specific to the survey year. Use of birth control pills and hormone therapy was self-reported by female participants. Self-reported sexual behavior datafor example, ever having had sex (vaginal, anal, or oral), sexual orientation, ever having had a same-sex sexual partner, number of oral sex partners during the past 12 months, age at first oral sex, and barrier use during oral sex in the past 12 monthswere collected at the MEC through a standardized questionnaire. History of herpes or warts and HPV infection also was self-reported. HIV positivity was based on HIV-antibody test results. Specimen Collection and Laboratory Methods A dental hygienist collected oral rinse specimens in sterile collection cups. Each participant was asked to swish a 10-mL sample of a mouthwash or sterile solution in his or her mouth and then expectorate the sample into the sterile cup. The MEC laboratory technologist transferred each sample from the collection cup to a 14-mL Falcon snap cap tube (Fisher Scientific) and shipped it to the laboratory for testing. Details of sample collection, quality control, and laboratory methods may be found in the MEC Laboratory Procedures Manual on the NHANES Web site (10) and in a previously published study (11). The specimens were analyzed as previously described (11). -Globinpositive samples were considered evaluable. Each purified DNA sample was analyzed by polymerase chain reaction assay. The Roche Linear Array HPV Genotyping test was used for detection of 37 HPV types, including high-risk types (HPV 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82) and low-risk types (HPV 6, 11, 40, 42, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 82 IS39 subtype, 83, 84, and 89 [cp6108]) (12). Concordance of Oral and Genital HPV Concurrent overall genital and oral HPV infection was defined as an infection in both the genital and oral regions, regardless of HPV type. Concurrent high-risk genital and oral HPV infection was defined as an infection with any high-risk type in both the genital and oral regions. Similarly, concurrent type-specific infection was defined as an infection with a specific HPV type (such as HPV 16) in the genital and oral regions. Details of specimen collection and laboratory methods for genital HPV detection among men and women may be found on the NHANES Web site and in previously published studies (13, 14). Statistical Analysis We estimated the prevalence of overall, high-risk, low-risk, and type-specific oral HPV, as well as prevalence by demographics and sexual behaviors, for men and women aged 18 to 69 years by using NHANES 2011 to 2014. Concordance of genital and oral HPV infection was estimated for adults aged 18 to 59 years by using NHANES 2013 to 2014. A survey designadjusted Wald F test was used for bivariate analyses, and the CochranArmitage test was performed to detect trends in prevalence. Prevalence estimates with a relative SE greater than 30% or based on 10 or fewer positive cases are noted; these are considered unstable and should be interpreted with caution. The differences in predicted probability between levels of risk factors for overall and high-risk oral HPV infection were estimated by using logistic regression models. Variables in logistic regression models were selected on the basis of bivariate associations. Statistical significance was tested at P < 0.05. All analyses were performed by using SAS 9.4 software (SAS Institute). For population estimates, we used SAS PROC SURVEY procedures, which included weight, cluster, and strata statements, to incorporate sampling weights. Role of the Funding Source The funders had no role in the study design or conduct or in the reporting of results. Results Analyses of overall and high-risk oral HPV infection included 4493 men and 4641 women (Supplement Figure 1). Supplement. Supplemental Tables and Figures Prevalence of Oral HPV Infection Among Men and Women The prevalence of overall oral HPV infection among men and women was 11.5% (95% CI, 9.8% to 13.1%) and 3.2% (CI, 2.7% to 3.8%), respectively, equating to 11 million men and 3.2 million women nationwide. Similarly, the prevalence of high-risk HPV infections was higher among men (7.3% [CI, 6.0% to 8.6%]; 7 million) than women (1.4% [CI, 1.0% to 1.8%]; 1.4 million) (P < 0.001). The type-specific prevalence of high-risk and low-risk HPV infection is shown in Figure 1, A and B, respectively. Notably, the prevalence of HPV 16, the most common type, was sixfold higher among men (1.8% [CI, 1.3% to 2.2%]; 1.7 million) than women (0.3% [CI, 0.1% to 0.5%]; 0.27 million) (P < 0.001). The prevalence of all high-risk and low-risk HPV types was consistently higher in men than women. The age-specific prevalence of vaccine-covered 9-valent, 4-valent, 2-valent, and HPV 16 subtypes among men and women is reported in Supplement Figure 2. Figure 1. Type-specific prevalence of oral HPV infection among men and women, NHANES 20112014. Errors bars represent 95% CIs. HPV= human papillomavirus; NHANES= National Health and Nutrition Examination Survey. A. Weighted prevalence of high-risk type-specific oral HPV infection among men and women. B. Weighted prevalence of low-risk type-specific oral HPV infection among men and women. Prevalence of Overall and High-Risk Oral HPV Infection by Demographic and Sexual Characteristics The prevalence of oral HPV infection by demographic characteristics is presented in Table 1. The overall prevalence in men followed a bimodal pattern, with prevalence peaks at ages 35 to 39 (12.2% [CI, 8.9% to 15.7%]) and 50 to 54 years (15.4% [CI, 10.2% to 20.5%]). The prevalence of high-risk HPV infection in men and overall and high-risk HPV infection in women did not differ significantly with regard to age. Non-Hispanic black men had the highest prevalence of overall (15.8%) and high-risk (8.8%) oral HPV infection, followed by white (overall, 11.7%; HR, 7.8%) and Hispanic (overall, 9.9%; high-risk, 5.5%) men. Table 1. Prevalence of Overall and High-Risk Oral HPV Infection in Men and Women, by Demographic Characteristics, NHANES 20112014 The prevalence of overall and high-risk oral HPV infection was significantly associated w


Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2016

Oncologic outcomes of surgically treated early-stage oropharyngeal squamous cell carcinoma

Jason I. Kass; Laureano Giraldez; William E. Gooding; Garret W. Choby; Seungwon Kim; Brett A. Miles; Marita Teng; Andrew G. Sikora; Jonas T. Johnson; Eugene N. Myers; Umamaheswar Duvvuri; Eric M. Genden; Robert L. Ferris

The purpose of this study was to characterize oncologic outcomes in early (T1–T2, N0) and intermediate (T1–T2, N1) oropharyngeal squamous cell carcinoma (SCC) after surgery.


Laryngoscope | 2015

Operative margin control with high‐resolution optical microendoscopy for head and neck squamous cell carcinoma

Brett A. Miles; Alexis Patsias; Timothy Quang; Alexandros D. Polydorides; Rebecca Richards-Kortum; Andrew G. Sikora

High‐resolution microendoscopy (HRME) provides real‐time visualization of the mucosal surface in the upper aerodigestive tract. This technology allows noninvasive discrimination of benign and neoplastic epithelium and has potential applications for intraoperative margin detection.


Translational Medicine | 2016

Vascular Aging: Implications for Cardiovascular Disease and Therapy

Yohannes T. Ghebre; Eduard Yakubov; Wing Tak Wong; Prasanna Krishnamurthy; Nazish Sayed; Andrew G. Sikora; Mark Bonnen

The incidence and prevalence of cardiovascular disease is highest among the elderly, in part, due to deleterious effects of advancing age on the heart and blood vessels. Aging, a known cardiovascular risk factor, is progressively associated with structural and functional changes to the vasculature including hemodynamic disturbance due to increased oxidative stress, premature cellular senescence and impairments in synthesis and/or secretion of endothelium-derived vasoactive molecules. These molecular and physiological changes lead to vessel wall stiffening and thickening, as well as other vascular complications that culminate to loss of vascular tone regulation and endothelial function. Intriguingly, the vessel wall, a biochemically active structure composed of collagen, connective tissue, smooth muscle and endothelial cells, is adversely affected by processes involved in premature or normal aging. Notably, the inner most layer of the vessel wall, the endothelium, becomes senescent and dysfunctional with advancing age. As a result, its ability to release vasoactive molecules such as acetylcholine (ACh), prostacyclin (PGI2), endothelium-derived hyperpolarizing factor (EDHF), and nitric oxide (NO) is reduced and the cellular response to these molecules is also impaired. By contrast, the vascular endothelium increases its generation and release of reactive oxygen (ROS) and nitrogen (RNS) species, vasoconstrictors such as endothelin (ET) and angiotensin (AT), and endogenous inhibitors of NO synthases (NOSs) to block NO. This skews the balance of the endothelium in favor of the release of highly tissue reactive and harmful molecules that promote DNA damage, telomere erosion, senescence, as well as stiffened and hardened vessel wall that is prone to the development of hypertension, diabetes, atherosclerosis and other cardiovascular risk factors. This Review discusses the impact of advancing age on cardiovascular health, and highlights the cellular and molecular mechanisms that underlie age-associated vascular changes. In addition, the role of pharmacological interventions in preventing or delaying age-related cardiovascular disease is discussed.


Cancer immunology research | 2015

Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy

Marina Moskalenko; Michael Pan; Yichun Fu; Ellen H. de Moll; Daigo Hashimoto; Arthur Mortha; Marylene Leboeuf; Padmini Jayaraman; Sebastian Bernardo; Andrew G. Sikora; Jedd D. Wolchok; Nina Bhardwaj; Miriam Merad; Yvonne Saenger

Moskalenko, Pan, and colleagues show in a B16 melanoma model that tumor clearance from the combined regimen of cytotoxic doses of cyclophosphamide and an antibody targeting melanoma differentiation antigen tyrosine-related protein 1 requires Fcγ receptors and innate CD90+NK1.1− lymphocytes, not classical NK cells. We sought to define cellular immune mechanisms of synergy between tumor-antigen–targeted monoclonal antibodies and chemotherapy. Established B16 melanoma in mice was treated with cytotoxic doses of cyclophosphamide in combination with an antibody targeting tyrosinase-related protein 1 (αTRP1), a native melanoma differentiation antigen. We find that Fcγ receptors are required for efficacy, showing that antitumor activity of combination therapy is immune mediated. Rag1−/− mice deficient in adaptive immunity are able to clear tumors, and thus innate immunity is sufficient for efficacy. Furthermore, previously treated wild-type mice are not significantly protected against tumor reinduction, as compared with mice inoculated with irradiated B16 alone, consistent with a primarily innate immune mechanism of action of chemo-immunotherapy. In contrast, mice deficient in both classical natural killer (NK) lymphocytes and nonclassical innate lymphocytes (ILC) due to deletion of the IL2 receptor common gamma chain IL2γc−/−) are refractory to chemo-immunotherapy. Classical NK lymphocytes are not critical for treatment, as depletion of NK1.1+ cells does not impair antitumor effect. Depletion of CD90+NK1.1− lymphocytes, however, both diminishes therapeutic benefit and decreases accumulation of macrophages within the tumor. Tumor clearance during combination chemo-immunotherapy with monoclonal antibodies against native antigen is mediated by the innate immune system. We highlight a novel potential role for CD90+NK1.1− ILCs in chemo-immunotherapy. Cancer Immunol Res; 3(3); 296–304. ©2015 AACR.


Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2016

Clinical characteristics and outcomes of oropharyngeal carcinoma related to high-risk non–human papillomavirus16 viral subtypes

Indu Varier; Brieze R. Keeley; Rosemarie Krupar; Alexis Patsias; Joanna Dong; Nikita Gupta; Arjun K. Parasher; Eric M. Genden; Brett A. Miles; Marita Teng; Richard L. Bakst; Vishal Gupta; Krzysztof Misiukiewicz; Elizabeth Y. Chiao; Michael E. Scheurer; Simon Laban; David Y. Zhang; Fei Ye; Miao Cui; Elizabeth G. Demicco; Marshall R. Posner; Andrew G. Sikora

The majority of human papillomavirus (HPV)‐related oropharyngeal carcinomas (OPCs) are associated with HPV genotype 16; however, OPC can be associated with other high‐risk non‐HPV16 genotypes.


Otolaryngology-Head and Neck Surgery | 2017

Factors Influencing Head and Neck Surgical Oncologists’ Transition from Curative to Palliative Treatment Goals

Kershena Liao; Jennifer Blumenthal-Barby; Andrew G. Sikora

Objective The factors influencing head and neck surgical oncologists’ goals of care and decisions to initiate conversations about transitioning to palliative-intent treatment for patients with limited curative treatment options are incompletely understood. Lack of guidance for physicians on this topic can lead to inconsistent utilization of palliative services, as well as confusing, upsetting experiences for patients and families. We review the literature investigating the clinical factors, inter- and intrapersonal factors, and financial and health care system considerations that head and neck cancer physicians weigh during this decision-making process. Data Sources PubMed. Review Methods Selected literature on head and neck surgical oncologists’ decision making in end-of-life care and palliative therapy was reviewed and analyzed thematically. Conclusions Physicians taking into account patients’ clinical trajectories often overestimate the negative impact of head and neck cancer symptoms on their quality of life, suggesting that patients’ expectations of quality of life should be discussed early, before communication barriers arise. How head and neck clinicians perceive and are influenced by patients’ desired degree of autonomy, which varies greatly depending on the severity of illness, is still unclear. Patients’ financial and insurance status affects decision making about hospice care. Finally, physician demographics (eg, age, subspecialization, practice setting), emotions, and philosophical background may exert unconscious biases that have not been fully determined for head and neck surgical oncologists. Implications for Practice A more comprehensive understanding of the head and neck surgical oncologist’s approach toward considering a transition to therapy with palliative intent may help guide advancements in this complex counseling process, leading to improvements in patient care, quality of life, and outcomes.


Cancer immunology research | 2016

Therapeutic HPV cancer vaccine targeted to CD40 elicits effective CD8+ T-cell immunity

Wenjie Yin; Dorothée Duluc; HyeMee Joo; Yaming Xue; Chao Gu; Zhiqing Wang; Lei Wang; Richard Ouedraogo; Lance Oxford; Amelia K. Clark; Falguni Parikh; Seunghee Kim-Schulze; LuAnn Thompson-Snipes; Sang-Yull Lee; Clay Beauregard; Jung-Hee Woo; Sandra Zurawski; Andrew G. Sikora; Gerard Zurawski; SangKon Oh

In the U.S., HPV is responsible for more than 26,000 new cancer cases annually. A novel and effective immunotherapeutic vaccine against many types of HPV16-associated cancers was developed that supports targeting vaccines to dendritic cells via CD40. Human papillomavirus (HPV), particularly HPV16 and HPV18, can cause cancers in diverse anatomical sites, including the anogenital and oropharyngeal (throat) regions. Therefore, development of safe and clinically effective therapeutic vaccines is an important goal. Herein, we show that a recombinant fusion protein of a humanized antibody to CD40 fused to HPV16.E6/7 (αCD40-HPV16.E6/7) can evoke HPV16.E6/7-specific CD8+ and CD4+ T-cell responses in head-and-neck cancer patients in vitro and in human CD40 transgenic (hCD40Tg) mice in vivo. The combination of αCD40-HPV16.E6/7 and poly(I:C) efficiently primed HPV16.E6/7-specific T cells, particularly CD8+ T cells, in hCD40Tg mice. Inclusion of montanide enhanced HPV16.E6/7-specific CD4+, but not CD8+, T-cell responses. Poly(I:C) plus αCD40-HPV16.E6/7 was sufficient to mount both preventative and therapeutic immunity against TC-1 tumors in hCD40Tg mice, significantly increasing the frequency of HPV16-specific CD8+ CTLs in the tumors, but not in peripheral blood. In line with this, tumor volume inversely correlated with the frequency of HPV16.E6/7-specific CD8+ T cells in tumors, but not in blood. These data suggest that CD40-targeting vaccines for HPV-associated malignancies can provide a highly immunogenic platform with a strong likelihood of clinical benefit. Data from this study offer strong support for the development of CD40-targeting vaccines for other cancers in the future. Cancer Immunol Res; 4(10); 823–34. ©2016 AACR.

Collaboration


Dive into the Andrew G. Sikora's collaboration.

Top Co-Authors

Avatar

Ravi Pathak

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Eric M. Genden

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Indu Varier

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Marshall R. Posner

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Rosemarie Krupar

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

David R. Rowley

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Falguni Parikh

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Krzysztof Misiukiewicz

Icahn School of Medicine at Mount Sinai

View shared research outputs
Researchain Logo
Decentralizing Knowledge